Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRLALT-D)
Investigating Survival in Patients Based on Donor Match Likelihood
Brief description of study.
The primary objective is to estimate and compare overall survival between the two arms: patients who are Very Likely to find a MUD versus those who are Very Unlikely to find a MUD.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Non-Hodgkin Lymphoma,Anaplastic Astrocytoma,Acute Myeloid Leukemia,Myelodysplatic syndromes,Hodgkin's Lymphoma,Acute Lymphoblastic Leukemia,Sickle Cell Disease
-
Age: 100 years or below
-
Gender: All
Inclusion Criteria
Patients of all ages with AML, ALL, MDS, NHL, HL, AA, or SCD are eligible.
Any planned conditioning regimen and GVHD prophylaxis approach is eligible.
Patients must be considered suitable allogeneic transplant candidates at the time of enrollment based on medical history, physical examination, and available laboratory tests. Specific testing for organ function is not required for eligibility but, if available, these tests should be used by the treating physician to judge transplant suitability.
Patient and physician must intend to proceed with allogeneic HCT within the next 6 months if a suitable donor is identified.
This study investigates the survival outcomes of patients with certain blood disorders who are likely or unlikely to find a matched unrelated donor (MUD) for a transplant. The conditions include acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), aplastic anemia (AA), and sickle cell disease (SCD). The study aims to understand whether the likelihood of finding a MUD affects overall survival.
Participants will be divided into two study arms based on their likelihood of finding a MUD. The study will compare the overall survival between these two arms. Various conditioning regimens and approaches to prevent graft-versus-host disease (GVHD) will be used, and patients will undergo allogeneic hematopoietic cell transplantation (HCT) if a suitable donor is found.
- Who can participate: Patients of any age with AML, ALL, MDS, NHL, HL, AA, or SCD can participate. They must be suitable candidates for allogeneic transplant and plan to proceed with it within 6 months if a donor is found.
- Study details: Participants will be divided into two arms based on their likelihood of finding a matched unrelated donor. They will undergo different conditioning regimens, which are treatments given to prepare the body for transplant, and graft-versus-host disease prevention approaches, which are methods used to prevent a condition where donor cells attack the recipient's body. A placebo is not involved in this study.